Article
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.
Human molecular genetics - 1 Sept 2011
Tanaka Yasuhito, Kurosaki Masayuki, Nishida Nao, Sugiyama Masaya, Matsuura Kentaro, Sakamoto Naoya, Enomoto Nobuyuki, Yatsuhashi Hiroshi, Nishiguchi Shuhei, Hino Keisuke, Hige Shuhei, Itoh Yoshito, Tanaka Eiji, Mochida Satoshi, Honda Masao, Hiasa Yoichi, Koike Asako, Sugauchi Fuminaka, Kaneko Shuichi, Izumi Namiki, Tokunaga Katsushi, Mizokami Masashi
Abstract excerpt
Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. The aim of this study was to identify host factors associated with IFN-induced thrombocytopenia by genome-wide association study (GWAS). In the GWAS stage using 900K single-nucleotide polymorphism (SNP)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
